Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

'The Pazdur Effect': A Tale Of Three US FDA Oncology Advisory Committee Meetings

Dec 20 2019

• By Kate Rawson

Richard Pazdur

Related Content

Oncology Pilot To Highlight Disagreements Between US FDA And Sponsor For Advisory Committees

Nov 15 2019

US FDA Pushes Back Against Critics: Breakthrough Is Not A Drug 'Beauty Contest'

Dec 11 2019

Lynparza, Keytruda Supplemental Indications Face US FDA Panel Review

Dec 02 2019

Keytruda Bladder Cancer Advisory Cmte. To Discuss Clinical Meaningfulness Of Complete Response Rate

Dec 16 2019

Merck's Keytruda Survives 'Conflicted' Adcom Vote For Bladder Cancer Indication

Dec 18 2019

Epizyme’s Tazemetostat Faces US FDA Doubts About Efficacy In Epithelioid Sarcoma

Dec 18 2019

AstraZeneca's Risky Lynparza Endpoint In Pancreatic Cancer Goes Before Advisory Cmte.

Dec 15 2019

Related Companies

AstraZeneca PLC

Merck & Co., Inc.

Bristol Myers Squibb Company

Epizyme, Inc.

Karyopharm Therapeutics

Daiichi Sankyo Co., Ltd.

Additional Topics

United States Advisory Committees Leadership Drug Review Drug Approval Standards FDA Regulation Cancer BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window